SEARCH

SEARCH BY CITATION

References

  • 1
    Russell RG. Bisphosphonates: the first 40 years. Bone. 2011 Jul; 49(1):219.
  • 2
    Ibrahim A, Scher N, Williams G, Sridhara R, Li N, Chen G, Leighton J, Booth B, Gobburu JV, Rahman A, Hsieh Y, Wood R, Vause D, Pazdur R. Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases. Clin Cancer Res. 2003 Jul; 9(7):23949.
  • 3
    Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, Satterfield S, Wallace RB, Bauer DC, Palermo L, Wehren LE, Lombardi A, Santora AC, Cummings SR; FLEX Research Group. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-Term Extension (FLEX): a randomized trial. JAMA. 2006 Dec 27; 296(24):292738.
  • 4
    Brown JE, Ellis SP, Lester JE, Gutcher S, Khanna T, Purohit OP, McCloskey E, Coleman RE. Prolonged efficacy of a single dose of the bisphosphonate zoledronic acid. Clin Cancer Res. 2007 Sep 15; 13(18 Pt 1):540610.
  • 5
    Grey A, Bolland MJ, Horne A, Wattie D, House M, Gamble G, Reid IR. Five years of anti-resorptive activity after a single dose of zoledronate: results from a randomized double-blind placebo-controlled trial. Bone. 2012 Jun; 50(6):138993.
  • 6
    Lund T, Abildgaard N, Delaisse JM, Plesner T. Effect of withdrawal of zoledronic acid treatment on bone remodelling markers in multiple myeloma. Br J Haematol. 2010 Oct; 151(1):923.
  • 7
    Badros A, Weikel D, Salama A, Goloubeva O, Schneider A, Rapoport A, Fenton R, Gahres N, Sausville E, Ord R, Meiller T. Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. J Clin Oncol. 2006 Feb 20; 24(6):94552.
  • 8
    Barasch A, Cunha-Cruz J, Curro FA, Hujoel P, Sung AH, Vena D, Voinea-Griffin AE, CONDOR Collaborative Group. Beadnell S, Craig RG, DeRouen T, Desaranayake A, Gilbert A, Gilbert GH, Goldberg K, Hauley R, Hashimoto M, Holmes J, Latzke B, Leroux B, Lindblad A, Richman J, Safford M, Ship J, Thompson VP, Williams OD, Yin W, Risk factors for osteonecrosis of the jaws: a case-control study from the CONDOR dental PBRN. J Dent.Res. 2011 Apr; 90(4):43944.
  • 9
    Woo SB, Hellstein JW, Kalmar JR. Systematic review: bisphosphonates and osteonecrosis of the jaws. Ann Int Med. 2006 May 16; 144(10):75361.
  • 10
    Aapro M, Abrahamsson PA, Body JJ, Coleman RE, Colomer R, Costa L, Crino L, Dirix L, Gnant M, Gralow J, Hadji P, Hortobagyi GN, Jonat W, Lipton A, Monnier A, Paterson AH, Rizzoli R, Saad F, Thürlimann B. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol. 2008 Mar; 19(3):42032.
  • 11
    Cremers S, Papapoulos S. Pharmacology of bisphosphonates. Bone. 2011 Jul; 49(1):429.
  • 12
    Hadji P. Managing bone health with zoledronic acid: a review of randomized clinical study results. Climacteric. 2011 Jun; 14(3):32132.
  • 13
    Hadji P, Gnant M, Aapro M, Lipton A, Coleman R. Dosing of zoledronic acid throughout the treatment continuum in breast cancer. Crit Rev Oncol Hematol. 2011 Aug; 79(2):17588.
  • 14
    Terpos E, Sezer O, Croucher PI, García-Sanz R, Boccadoro M, San Miguel J, Ashcroft J, Bladé J, Cavo M, Delforge M, Dimopoulos MA, Facon T, Macro M, Waage A. Sonneveld P; European Myeloma Network. The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network. Ann Oncol. 2009 Aug 1; 20(8):130317.
  • 15
    Chen T, Berenson J, Vescio R, Swift R, Gilchick A, Goodin S, LoRusso P, Ma P, Ravera C, Deckert F, Schran H, Seaman J, Skerjanec A. Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. J Clin Pharmacol. 2002 Nov 1; 42(11):122836.
  • 16
    Skerjanec A, Berenson J, Hsu C, Major P, Miller WH, Ravera C, Schran H, Seaman J, Waldmeier F. The pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with varying degrees of renal function. J Clin Pharmacol. 2003 Feb 1; 43(2):15462.
  • 17
    Cremers SC, Papapoulos SE, Gelderblom H, Seynaeve C, den Hartigh J, Vermeij P, van derRijt CC, van Zuylen L. Skeletal retention of bisphosphonate (pamidronate) and its relation to the rate of bone resorption in patients with breast cancer and bone metastases. J Bone Miner Res. 2005; 20(9):15437.
  • 18
    Cremers SC, Eekhoff ME, den Hartigh J, Hamdy NA, Vermeij P, Papapoulos SE. Relationships between pharmacokinetics and rate of bone turnover after intravenous bisphosphonate (olpadronate) in patients with Paget's disease of bone. J Bone Miner Res. 2003; 18(5):86875.
  • 19
    Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, Apffelstaedt J, Hussein M, Coleman RE, Reitsma DJ, Seaman JJ, Chen BL, Ambros Y. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J. 2001 Sep; 7(5):37787.
  • 20
    Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, Apffelstaedt J, Hussein MA, Coleman RE, Reitsma DJ, Chen BL, Seaman JJ. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma. Cancer. 2003; 98(8):173544.
  • 21
    Clarke DP, Meancock C, McCready VR. The doughnut sign in patients with multiple myeloma. Nucl Med Commun. 1986 Apr; 7(4):23943.
  • 22
    Woolfenden JM, Pitt MJ, Durie BG, Moon TE. Comparison of bone scintigraphy and radiography in multiple myeloma. Radiology. 1980 Mar; 134(3):7238.
  • 23
    Bataille R, Chevalier J, Rossi M, Sany J. Bone scintigraphy in plasma-cell myeloma. A prospective study of 70 patients. Radiology. 1982 Dec 1; 145(3):8014.
  • 24
    Goergen TG, Alazraki NP, Halpern SE, Heath V, Ashburn WL.Cold” bone lesions: a newly recognized phenomenon of bone imaging. J Nucl Med. 1974 Dec 1; 15(12):11204.
  • 25
    Sadik M, Suurkula M, Hoglund P, Jarund A, Edenbrandt L. Quality of planar whole-body bone scan interpretations—a nationwide survey. Eur J Nucl Med Mol Imaging. 2008 Aug; 35(8):146472.
  • 26
    Sy WM, Westring DW, Weinberger G.Cold” lesions on bone imaging. J Nucl Med. 1975 Nov 1; 16(11):10136.
  • 27
    Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976; 16(1):3141.
  • 28
    Rajkumar SV, Harousseau JL, Durie B, Anderson KC, Dimopoulos M, Kyle R, Blade J, Richardson P, Orlowski R, Siegel D, Jagannath S, Facon T, Avet-Loiseau H, Lonial S, Palumbo A, Zonder J, Ludwig H, Vesole D, Sezer O, Munshi NC, San Miguel J; International Myeloma Workshop Consensus Panel 1. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood. 2011 May 5; 117(18):46915.
  • 29
    Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000 Feb 2; 92(3):20516.
  • 30
    Legay F, Gauron S, Deckert F, Gosset G, Pfaar U, Ravera C, Wiegand H, Schran H. Development and validation of a highly sensitive RIA for zoledronic acid, a new potent heterocyclic bisphosphonate, in human serum, plasma and urine. J Pharm Biomed Anal. 2002 Nov 7; 30(4):89711.
  • 31
    Lund T, Abildgaard N, Andersen TL, Delaisse JM, Plesner T. Multiple myeloma: changes in serum C-terminal telopeptide of collagen type I and bone-specific alkaline phosphatase can be used in daily practice to detect imminent osteolysis. Eur J Haematol. 2010 May; 84(5):41220.
  • 32
    Berenson Rosen L, Vescio R, Lau HS, Woo M, Sioufi A, Kowalski MO, Knight RD, Seaman JJ. Pharmacokinetics of pamidronate disodium in patients with cancer with normal or impaired renal function. J Clin Pharmacol. 1997 Apr 1; 37(4):28590.
  • 33
    Cremers S, Sparidans R, den HJ, Hamdy N, Vermeij P, Papapoulos S. A pharmacokinetic and pharmacodynamic model for intravenous bisphosphonate (pamidronate) in osteoporosis. Eur J Clin Pharmacol. 2002 Feb; 57(12):88390.
  • 34
    Cremers SC, Pillai GC, Papapoulos SE. Pharmacokinetics/pharmacodynamics of bisphosphonates: use for optimisation of intermittent therapy for osteoporosis. Clin Pharmacokinet. 2005 Apr; 44(6):55170.
  • 35
    Khan SA, Kanis JA, Vasikaran S, Kline WF, Matuszewski BK, McCloskey EV, Beneton MN, Gertz BJ, Sciberras DG, Holland SD, Orgee J, Coombes GM, Rogers SR, Porras AG. Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis. J Bone Miner Res. 1997; 12(10):17007.
  • 36
    Schoenberger J, Rozeboom S, Wirthgen-Beyer E, Eilles C. Evaluation of the clinical value of bone metabolic parameters for the screening of osseous metastases compared to bone scintigraphy. BMC Nucl Med. 2004 Dec 4; 4(1):3.
  • 37
    Fogelman I, Bessent R. Age-related alterations in skeletal metabolism—24-hr whole-body retention of diphosphonate in 250 normal subjects: concise communication. J Nucl Med. 1982 Apr 1; 23(4):296300.
  • 38
    Weiss HM, Pfaar U, Schweitzer A, Wiegand H, Skerjanec A, Schran H. Biodistribution and plasma protein binding of zoledronic acid. Drug Metab Dispos. 2008 Oct; 36(10):20439.
  • 39
    Azuma Y, Sato H, Oue Y, Okabe K, Ohta T, Tsuchimoto M, Kiyoki M. Alendronate distributed on bone surfaces inhibits osteoclastic bone resorption in vitro and in experimental hypercalcemia models. Bone. 1995 Feb; 16(2):23545.
  • 40
    Clemons M, Dranitsaris G, Ooi W, Cole DE. A Phase II trial evaluating the palliative benefit of second-line oral ibandronate in breast cancer patients with either a skeletal related event (SRE) or progressive bone metastases (BM) despite standard bisphosphonate (BP) therapy. Breast Cancer Res Treat. 2008; Mar; 108(1):7985.
  • 41
    Vogel MN, Weisel K, Maksimovic O, Peters S, Brodoefel H, Claussen CD, Horger MS. Pathologic fractures in patients with multiple myeloma undergoing bisphosphonate therapy: incidence and correlation with course of disease. AJR Am J Roentgenol. 2009 Sep 1; 193(3):65661.
  • 42
    Henk H, Teitelbaum A, Kaura S. Evaluation of the clinical benefit of long-term (beyond 2 years) treatment of skeletal-related events in advanced cancers with zoledronic acid. Curr Med Res Opin. 2012 Jul; 28(7):111927.
  • 43
    Morgan GJ, Child JA, Gregory WM, Szubert AJ, Cocks K, Bell SE, Navarro-Coy N, Drayson MT, Owen RG, Feyler S, Ashcroft AJ, Ross FM, Byrne J, Roddie H, Rudin C, Cook G, Jackson GH, Wu P, Davies FE; National Cancer Research Institute Haematological Oncology Clinical Studies Group. Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial. Lancet Oncol. 2011 Aug; 12(8):74352.
  • 44
    Hauge EM, Qvesel D, Eriksen EF, Mosekilde L, Melsen F. Cancellous bone remodeling occurs in specialized compartments lined by cells expressing osteoblastic markers. J Bone Miner Res. 2001; 16(9):157582.
  • 45
    Andersen TL, Sondergaard TE, Boissy P, Skorzynska KE, Plesner TL, Hauge E, Plesner T, Delaisse JM. Identification of a highly specialized micro-anatomical structure that is a key player in myeloma bone disease 1. Haematologica. 2007; 92(6):127.
  • 46
    Andersen TL, Soe K, Sondergaard TE, Plesner T, Delaisse JM. Myeloma cell-induced disruption of bone remodelling compartments leads to osteolytic lesions and generation of osteoclast-myeloma hybrid cells. Br J Haematol. 2010 Feb 1; 148(4):55161.
  • 47
    Kristensen HB, Andersen TL, Marcussen N, Rolighed L, Delaissé JM. Increased presence of capilaries next to bone remodeling sites in adult human cancellous bone. J Bone Mineral Res. 2013 Mar; 28(3):57485.
  • 48
    Jensen PR, Andersen TL, Soe K, Hauge EM, Bollerslev J, Amling M, Barvencik F, Delaisse JM. Premature loss of bone remodeling compartment canopies is associated with deficient bone formation: a study of healthy individuals and patients with Cushing's syndrome. J Bone Miner Res. 2012 Apr; 27(4):77080.
  • 49
    Guise TA, Brufsky A, Coleman RE. Understanding and optimizing bone health in breast cancer. Curr Med Res Opin. 2010 Dec; 26(Suppl 3):320.
  • 50
    Richardson PG, Laubach JP, Schlossman RL, Ghobrial IM, Mitsiades CS, Rosenblatt J, Mahindra A, Raje N, Munshi N, Anderson KC. The Medical Research Council Myeloma IX trial: the impact on treatment paradigms. Eur J Haematol. 2012 Jan; 88(1):17.